한국 유방암 환자에서 혈청 1,25-Dihydroxyvitamin D 수치와 예후와의 관계에 대한 고찰
Correlation between Serum 1,25-Dihydroxyvitamin D Levels and Breast Cancer Prognosis in Korea
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: As there is growing evidence that the vitamin D status is correlated with breast cancer prognosis, in this study, we investigated the correlation between serum 1,25-dihydroxyvitamin D levels and the prognosis of patients with breast cancer in a Korean cohort. Methods: We performed a retrospective analysis of 436 Korean patients with breast cancer who were diagnosed between January 2000 and December 2008. According to the serum 1,25-dihydroxyvitamin D levels, the patients were divided into the following two groups: group 1 (<29.75 ng/mL) and group 2 (≥29.75 ng/mL). Survival curves were obtained by using the Kaplan-Meier method. Univariate and multivariate analyses were also conducted to assess the independent prognostic significance of serum 1,25-dihydroxyvitamin D levels. Results: During a mean period of 84.66±29.29 months, 51 patients experienced tumor recurrence and 22 patients died. On survival analysis, group 1 showed poorer disease-free survival, especially for patients with luminal type breast cancer. Univariate and multivariate analyses showed that the 1,25-dihydroxyvitamin D status was a significant prognostic factor for disease-free survival, only in patients with luminal type breast cancer. Conclusion: The serum 1,25-dihydroxyvitamin D status can influence disease-free survival in Korean patients with breast cancer, particularly in those with luminal type breast cancer.
Abstract
Purpose: As there is growing evidence that the vitamin D status is correlated with breast cancer prognosis, in this study, we investigated the correlation between serum 1,25-dihydroxyvitamin D levels and the prognosis of patients with breast cancer in a Korean cohort. Methods: We performed a retrospective analysis of 436 Korean patients with breast cancer who were diagnosed between January 2000 and December 2008. According to the serum 1,25-dihydroxyvitamin D levels, the patients were divided into the following two groups: group 1 (<29.75 ng/mL) and group 2 (≥29.75 ng/mL). Survival curves were obtained by using the Kaplan-Meier method. Univariate and multivariate analyses were also conducted to assess the independent prognostic significance of serum 1,25-dihydroxyvitamin D levels. Results: During a mean period of 84.66±29.29 months, 51 patients experienced tumor recurrence and 22 patients died. On survival analysis, group 1 showed poorer disease-free survival, especially for patients with luminal type breast cancer. Univariate and multivariate analyses showed that the 1,25-dihydroxyvitamin D status was a significant prognostic factor for disease-free survival, only in patients with luminal type breast cancer. Conclusion: The serum 1,25-dihydroxyvitamin D status can influence disease-free survival in Korean patients with breast cancer, particularly in those with luminal type breast cancer.
참고문헌 (28)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-2007", Journal of Korean Medical Science, 25(8), pp.1113~1121 (2010), 대한의학회
- Jin-Hee Lee, "Population-based Breast Cancer Statistics in Korea during 1993-2002:Incidence, Mortality, and Survival", Journal of Korean Medical Science, 22(S), pp.11~16 (2007), 대한의학회
- The Korean Breast Cancer Society, "Nationwide Korean breast cancer data of 2004 using breast cancer registration program", J Breast Cancer, 9, pp.151~161 (2006)
- Son BH, "Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years", Arch Surg, 141, pp.155~160 (2006)
- 정규원, "Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study", Cancer Research and Treatment, 45(3), pp.162~171 (2013), 대한암학회
- Holick MF, "Evolution and function of vitamin D", Recent Results Cancer Res, 164, pp.3~28 (2003)
- Holick MF, "Vitamin D deficiency", N Engl J Med, 357, pp.266~281 (2007)
- Bikle D, "Nonclassic actions of vitamin D", J Clin Endocrinol Metab, 94, pp.26~34 (2009)
- Lundqvist J, "1alpha,25-Dihydroxyvitamin D3 inhibits cell growth and NFkappaB signaling in tamoxifen-resistant breast cancer cells", Steroids, 85, pp.30~35 (2014)
- Neuhouser ML, "Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors", Am J Clin Nutr, 88, pp.133~139 (2008)
- Freedman DM, "Prospective study of serum vitamin D and cancer mortality in the United States", J Natl Cancer Inst, 99, pp.1594~1602 (2007)
- Goodwin PJ, "Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer", J Clin Oncol, 27, pp.3757~3763 (2009)
- Vrieling A, "Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study", Breast Cancer Res, 13, pp.R74~ (2011)
- Hatse S, "Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency", Carcinogenesis, 33, pp.1319~1326 (2012)
- Villaseñor A, "Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors", Cancer Causes Control, 24, pp.759~767 (2013)
- McCullough ML, "Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers", Am J Epidemiol, 172, pp.21~35 (2010)
- Matthews D, "Genomic vitamin D signaling in breast cancer: insights from animal models and human cells", J Steroid Biochem Mol Biol, 121, pp.362~367 (2010)
- Escaleira MT, "Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation", Breast Cancer Res Treat, 54, pp.123~133 (1999)
- Katayama ML, "Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line", J Steroid Biochem Mol Biol, 84, pp.57~69 (2003)
- Verlinden L, "Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo", Cancer Res, 60, pp.2673~2679 (2000)
- Saez S, "McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo", Breast Cancer Res Treat, 27, pp.69~81 (1993)
- Welsh J, "Vitamin D-3 receptor as a target for breast cancer prevention", J Nutr, 133(7 Suppl), pp.2425S~2433S (2003)
- Hewison M, "1alpha-Hydroxylase and the action of vitamin D", J Mol Endocrinol, 25, pp.141~148 (2000)
- Janowsky EC, "Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk", Public Health Nutr, 2, pp.283~291 (1999)
- Stoica A, "Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells", J Cell Biochem, 75, pp.640~651 (1999)
- Swami S, "1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells", Clin Cancer Res, 6, pp.3371~3379 (2000)
- Flanagan L, "Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion", J Steroid Biochem Mol Biol, 84, pp.181~192 (2003)